Theriva Biologics 获得 FDA 对其胰腺癌药物 VCN-01 的 3 期研究的指导。 Theriva Biologics gets FDA guidance for a Phase 3 study on its pancreatic cancer drug VCN-01.

美国FDA已向Theriva Biologics提供了关于VCN-01的第三期研究设计的指导,这是一种潜在的转移性胰腺癌治疗方法. Theriva Biologics has received guidance from the U.S. FDA on the design of its Phase 3 study for VCN-01, a potential treatment for metastatic pancreatic cancer. 该公司将利用这一指南推进临床试验,以评价该药物对这种致命疾病的效力和安全性。 The company will use this guidance to advance the clinical trial aimed at evaluating the efficacy and safety of the drug for this deadly disease.